The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition
about
Investigations into the auto-FAT10ylation of the bispecific E2 conjugating enzyme UBA6-specific E2 enzyme 1HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?Disruption of FAT10-MAD2 binding inhibits tumor progression.Dissecting interferon-induced transcriptional programs in human peripheral blood cells.HDAC6 and Ubp-M BUZ domains recognize specific C-terminal sequences of proteins.The inherited blindness protein AIPL1 regulates the ubiquitin-like FAT10 pathwayUbiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery.Identification of a novel binding protein of FAT10: eukaryotic translation elongation factor 1A1.Factors regulated by interferon gamma and hypoxia-inducible factor 1A contribute to responses that protect mice from Coccidioides immitis infectionConjugation of the ubiquitin activating enzyme UBE1 with the ubiquitin-like modifier FAT10 targets it for proteasomal degradation.FAT10 is a proteasomal degradation signal that is itself regulated by ubiquitination.Lactobacillus paracasei and Lactobacillus plantarum strains downregulate proinflammatory genes in an ex vivo system of cultured human colonic mucosaUbiquitin-like modifier FAT10 attenuates RIG-I mediated antiviral signaling by segregating activated RIG-I from its signaling platformReplication and further characterization of a Type 1 diabetes-associated locus at the telomeric end of the major histocompatibility complexFAT10 is associated with the malignancy and drug resistance of non-small-cell lung cancerChromatin-remodelling proteins of the pea aphid, Acyrthosiphon pisum (Harris).Virus-induced autoimmune diabetes in the LEW.1WR1 rat requires Iddm14 and a genetic locus proximal to the major histocompatibility complex.Ubiquitin-like protein FAT10 promotes bladder cancer progression by stabilizing survivin.To prevent neurodegeneration: HDAC6 uses different strategies for different challenges.Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies.FAT10, an ubiquitin-like protein, confers malignant properties in non-tumorigenic and tumorigenic cells.NUB1 modulation of GSK3β reduces tau aggregation.FAT10: a novel mediator of Vpr-induced apoptosis in human immunodeficiency virus-associated nephropathy.Aggresome-like structure induced by isothiocyanates is novel proteasome-dependent degradation machinery.Ubiquitin signaling and autophagy.Newly translated proteins are substrates for ubiquitin, ISG15, and FAT10.UBD modifies APOL1-induced kidney disease risk.
P2860
Q24337322-E023D466-80AB-4B7B-A936-42D8FC3B7FE5Q27015801-0FCA2983-B699-4422-9913-2C26951A1900Q31814836-374EB725-34CD-4B0B-BAD5-41DB91D5E140Q33546362-499329CF-5BB1-43C0-8788-3DB2432ACE77Q33751395-F6F408E8-E8ED-45F3-9192-BA1CC0D5FF78Q34162616-CF807D81-6BDB-4A7A-BE73-3988226F6AF4Q34250198-ED565074-0714-4EC5-B380-D7311E6639BAQ34262716-249F893E-2D7C-4743-B52C-2EE1CC82B8DAQ34420458-FC2B61FA-FBE3-487B-B218-101776129EC2Q34467024-C134BD41-7D27-4EE2-9868-03986B1BF61CQ35642892-B5E56DA7-5E18-4F2D-B299-9D8553EA640DQ36620029-51B4C8ED-7A43-4DBF-BAD9-102175656613Q36707766-D6766775-4D08-4816-8692-9A6BE9921E3EQ36722514-F38EB61E-9E05-4F40-AC34-BBFF59DED834Q37122789-D0B0428C-23AC-4606-8BD0-E8A15A3A8ED3Q37353773-C0761E53-8EA0-4D79-BDD9-8447B008E307Q37429158-E73FA9C0-72E1-4F0A-BCF3-F6B841C9E04AQ37697183-59052A57-BB42-49C4-8031-762AFD3B40FDQ37886710-274A5B3A-1346-436B-818D-7A9F6DE3CC51Q38828275-49F21214-D435-4519-A02E-CE7F01C54C31Q39044717-3FC12A31-5BCB-4841-9FE6-90D8201C5B55Q39281484-C2BA1538-C047-4427-A783-AF7CB5A55C48Q39804433-DD60512C-3AE2-455B-A7BC-0F265DD14D80Q42561802-21003F2D-EAD0-45D7-A2E9-FD5EA0E1E378Q47349935-CB7A5354-3D42-4534-9813-4905E63DDD12Q51281230-BF23AD92-D93B-4BA4-9F33-D2B8EEFCCE58Q52659610-15621EEA-890B-4AFD-BA56-08729D9CAD9D
P2860
The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@ast
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@en
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@en-gb
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@nl
type
label
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@ast
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@en
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@en-gb
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@nl
prefLabel
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@ast
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@en
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@en-gb
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@nl
P921
P3181
P356
P1476
The ubiquitin-like modifier FA ...... es under proteasome inhibition
@en
P2093
Birte Kalveram
Gunter Schmidtke
P304
P3181
P356
10.1242/JCS.035006
P407
P577
2008-12-15T00:00:00Z